An evaluation of the cytochrome P450 induction potential of pantoprazole in primary human hepatocytes

Chemico-Biological Interactions

Volumn 114, Issue 1-2, 1998, Pages 1-13

  Masubuchi, Noriko ^a   Li, Albert P ^b   Okazaki, Osamu ^a  

^a Drug Metab and Analyt Chem R   (Japan)

^b In Vitro Technologies Inc   (United States)

Author keywords

CYP1A; CYP3A; Cytochrome P450; Lansoprazole; Omeprazole; Pantoprazole; Primary human hepatocyte; Proton pump inhibitor

Indexed keywords

3 METHYLCHOLANTHRENE; CYTOCHROME P450; ETHOXYRESORUFIN DEETHYLASE; ISOENZYME; LANSOPRAZOLE; OMEPRAZOLE; OXYGENASE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RIFAMPICIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG INTERACTION; ENZYME INDUCTION; FEMALE; HUMAN; HUMAN CELL; LIVER CELL CULTURE; MALE;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; AGED; BENZIMIDAZOLES; BLOTTING, WESTERN; CELLS, CULTURED; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INDUCTION; FEMALE; HUMANS; LIVER; MALE; METHYLCHOLANTHRENE; MIDDLE AGED; OMEPRAZOLE; RIFAMPIN; STEROID HYDROXYLASES; STRUCTURE-ACTIVITY RELATIONSHIP; SULFOXIDES;

EID: 0032479408     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-2797(98)00031-3     Document Type: Article

References (24)

1. Simon B., Müller P., Marinis E., Lührmann R., Huber R., Hartmann M., Wurst W. Effect of repeated oral administration of BY 1023/SK&F96022-a new substituted benzimidazole derivative-on pentagastrin-stimulated gastric acid secretion and pharmacokinetics in man. Aliment. Pharmacol. Ther. 4:1990;373-379.
2. Krusekopf S., Kleeberg U., Hildebrandt A.G., Ruckpaul K. Effects of benzimidazole derivatives on cytochrome P450 1A1 expression in a human hepatoma cell line. Xenobiotica. 27:1997;1-9.
3. Masubuchi N., Hakusui H., Okazaki O. Effects of pantoprazole on xenobiotic metabolizing enzymes in rat liver microsomes: a comparison with other proton pump inhibitors. Drug. Metab. Disp. 25:1997;584-589.
4. A.P. Li, Primary hepatocyte culture as an in vitro toxicological system, in: S. Gad (Ed.), In Vitro Toxicology, Raven Press, New York, 1994, pp. 195-220.
5. 2 antagonists, in rat and human hepatocyte cultures. Xenobiotica. 24:1994;25-36.
6. Jurima-Romet M., Huang H.S., Beck D.J., Li A.P. Evaluation of drug interactions in intact hepatocytes: Inhibitors of terfenadine metabolism. Toxicol. In Vitro. 10:1996;655-663.
7. Li A.P., Kaminski D.L., Rasmussen A. Substrates of human hepatic cytochrome P4503A4. Toxicology. 104:1995;1-8.
8. Li A.P., Rasmussen A., Xu L., Kaminski D.L. Rifampicin induction of lidocaine metabolism in cultured human hepatocytes. J. Pharmacol. Exp. Ther. 274:1995;673-677.
9. Diaz D., Fabre I., Daujat M., Aubert B.S., Bories P., Michel H., Maurel P. Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450. Gastroenterology. 99:1990;737-747.
10. Curi-Pedrosa R., Daujat M., Pichard L., Ourlin J.C., Clair P., Gervot L., Lesca P., Domergue J., Joyeux H., Fourtanier G., Maurel P. Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture. J. Pharmacol. Exp. Ther. 269:1994;384-392.
11. 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. Clin. Pharmacol. Ther. 52:1992;170-180.
12. Nousbaum J.B., Berthou F., Carlhant D., Riche C., Robaszkiewicz M., Gouerou H. Four week treatment with omeprazole increases the metabolism of caffeine. Am. J. Gastroenterol. 89:1994;371-375.
13. Kokufu T., Ihara N., Sugioka N., Koyama H., Ohta T., Mori S., Nakajima K. Effects of lansoprazole on pharmacokinetics and metabolism of theophylline. Eur. J. Clin. Pharmacol. 48:1995;391-395.
14. Li A.P., Roque M.A., Beck D.J., Kaminski D.L. Isolation and culturing of hepatocytes from human liver. J. Tissue Culture Meth. 14:1992;139-146.
15. Burke M.D., Thompson S., Elcombe C.R., Halpert J., Haaparanta T., Mayer R.T. Ethoxy-, pentoxy- and benzyloxyphenoxazones and homologues: a series of substrates to distinguish between different induced cytochromes P450. Biochem. Pharmacol. 34:1985;3337-3345.
16. Sonderfan A.J., Arlotto M.P., Dutton D.R., McMillen S.K., Parkinson A. Regulation of testosterone hydroxylation by rat liver microsomal cytochrome P450. Arch. Biochem. Biophys. 255:1987;27-41.
17. Funae Y., Imaoka S. Purification and characterization of liver microsomal cytochrome P450 from untreated male rats. Biochim. Biophys. Acta. 926:1987;349-358.
18. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.
19. Guengerich F.P., Wang P., Davidson P., Davidson N.K. Estimation of isozymes of microsomal cytochrome P-450 in rats, rabbits, and humans using immunochemical staining coupled with sodium dodecyl sulfate polyacrylamide gel electrophoresis. Biochemistry. 21:1982;1698-1706.
20. Gonzalez F.J., Gelboin H.V. Role of human cytochromes P450 in the metabolic activation chemical carcinogens and toxins. Drug Metab. Rev. 26:1994;165-183.
21. Pue M.A., Laroche J., Meineke I., de Mey C. Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects. Eur. J. Clin. Pharmacol. 44:1993;575-578.
22. Blum R.A. Lansoprazole and omeprazole in the treatment of acid peptic disorders. Am. J. Health-Syst Pharm. 53:1996;1401-1415.
23. Fuchs W., Sennewald R., Klotz U. Lansoprazole does not affect the bioavailability of oral contraceptives. Br. J. Clin. Pharmacol. 38:1994;376-380.
24. Masubuchi N., Okazaki O. An evaluation of the CYP1A induction potential of pantoprazole in primary rat hepatocytes: a comparison with other proton pump inhibitors. Chemico-Biol. Interact. 107:1997;63-74.